Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon Dec 03, 2021 2:55pm
191 Views
Post# 34196217

RE:RE:RE:RE:RE:By and large

RE:RE:RE:RE:RE:By and large Great post as usual MM.  You are spot on the money even if Spectral management and governance aren't.

Or are they?  If deals already lined up with Baxter and perhaps DaVita then no need to do a Nasdaq listing.  Why bother if the range of proceeds have already been defined? And all signs - in spite of encouraging words - point to no listing actually planned to be done.  But may as well keep them guessing.

And placing the future in purgatory is a stroke of genius.  Telling the unwashed masses that nothing will happen until it happens virtually ensures the share price stays constant until they make something happen.  And at these share price levels future options remain cheap.  And no pressing reason to exercise existing options since they're out of the money.  If they got to the strike price they'd have to be exercised so gains taxed as capital gains rather than full income inclusion.  But until then you just keep your after tax income ready for deployment.

And the peripheral players and semi insiders can also enjoy the same benefits with new raises.  I see huge benefits for the insiders to a low share price and no "catalysts" in the short term in spite of suggesting there is no benefit to them.  Who says mediocre performance doesn't pay?
<< Previous
Bullboard Posts
Next >>